GNRH1 and breast cancer: Goserelin is a potent luteinizing hormone-releasing hormone (LH-RH) agonistic analog that can be used for the treatment of hormone responsive tumors.[10] Daily administration of LH-RH agonist analogs leads to pituitary desensitization and a decrease in gonadotrophin release, which in turn produces gonadal atrophy and a decrease in sex steroid secretion.[20] Goserelin has also been shown to be effective against DMBA (dimethylbenzanthracene) – induced rat mammary tumors[21, 22] and we previously observed an important regression in NMU tumor development after chronic goserelin treatment.